Michaeli, Daniel Dr. med.; Dr. rer. oec.Universität HeidelbergHeidelberg
Publikationsliste einschränken
Publikationsjahre
Publikationstypen
Sprache
Co-Autoren (Uni Heidelberg)
Co-Autoren (extern)
Neueste Publikationen in heiBIB 
(ingesamt sind 30 Publikationen erfasst)
- Michaeli, Daniel: Value-based indication-specific pricing and weighted-average pricing : estimated price and cost savings for cancer drugs / Daniel Tobias Michaeli, Thomas Michaeli, April 2025. - 13 S.
In: PharmacoEconomics, ISSN 1179-2027. 43(2025), 4 vom: Apr., Seite 415-427
DOI: 10.1007/s40273-024-01448-x
- Michaeli, Daniel: The healthcare workforce shortage of nurses and physicians : practice, theory, evidence, and ways forward / Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Thomas Michaeli. -
Los Angeles: Sage, 2024. - 1 Online-Ressource (12 Seiten) : Diagramme
DOI: 10.11588/heidok.00036055
- Michaeli, Daniel: Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention / vorgelegt von Daniel Tobias Michaeli ; Referent: Priv.-Doz. Dr. med. Tobias Boch. -
Heidelberg, 2024. - 98 Blätter : Illustrationen, Diagramme
- Michaeli, Julia: Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price / Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel W… , November 2024. - 12 S.
In: Breast cancer, ISSN 1880-4233. 31(2024), 6 vom: Nov., Seite 1144-1155
DOI: 10.1007/s12282-024-01634-x
- Michaeli, Daniel: Clinical trial design and treatment effects : a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications / Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli, September 20, 2024. - 9 S.
In: BMJ evidence-based medicine, ISSN 2515-4478. 29(2024), 5 vom: Sept., Seite 333-341
DOI: 10.1136/bmjebm-2023-112544
- Michaeli, Daniel: Breakthrough therapy cancer drugs and indications with FDA approval : development time, innovation, trials, clinical benefit, epidemiology, and price / Daniel Tobias Michaeli, MSc, MSc, and Thomas Michaeli, MD, MSc, MSc, May 2024. - 9 S. : Illustrationen
In: Journal of the National Comprehensive Cancer Network, ISSN 1540-1413. 22(2024), 4, Seite 1-9
DOI: 10.6004/jnccn.2023.7110
- Michaeli, Daniel: Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention / vorgelegt von Daniel Tobias Michaeli ; Referent: Priv.-Doz. Dr. med. Tobias Boch. -
Heidelberg, 26 Nov. 2024. - 1 Online-Ressource (98 Seiten) : Illustrationen, Diagramme
DOI: 10.11588/heidok.00035637
- Michaeli, Christoph T.: Partial orphan cancer drugs : US food and drug administration approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending / Thomas Michaeli, Daniel Tobias Michaeli, 18 January 2024. - 9 S.
In: Value in health, ISSN 1524-4733. 27(2024), 4, Seite 449-457
DOI: 10.1016/j.jval.2024.01.002
- Michaeli, Daniel: Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs / Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli, September 2024. - 13 S. : Illustrationen
In: Targeted oncology, ISSN 1776-260X. 19(2024), 5 vom: Sept., Seite 797-809
DOI: 10.1007/s11523-024-01081-w
- Michaeli, Daniel: Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy / Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Tobias Boch, Julia Caroline Michaeli, 2024. - 19 S. : Illustrationen
In: The European journal of health economics, ISSN 1618-7601. 25(2024), 6 vom: Aug., Seite 979-997
DOI: 10.1007/s10198-023-01639-x
IDs
Links
Michaeli, Daniel in ...
Export Publikationsliste
heiBIB
Bei fehlerhaften oder unvollständigen Angaben wenden Sie sich bitte an biblio@ub.uni-heidelberg.de.
Informationen zu heiBIB (inkl. Einbettung der Publikationslisten in eigene WWW-Seiten).
